Effects of Switching from Agalsidase Beta to Agalsidase Alfa in 10 Patients with Anderson-Fabry Disease
Authors:
- 21 October 2012
- book chapter
- Published by Springer Nature
- Vol. 9, 41-48
Abstract
Anderson-Fabry disease (AFD) is a multiorgan X-linked lysosomal storage disease that particularly affects the heart, kidneys, and cerebrovascular system. Current treatment is enzyme replacement therapy (ERT) with agalsidase beta (Fabrazyme®, Genzyme Corporation, Cambridge, MA, USA) or agalsidase alfa (Replagal®, Shire Human Genetic Therapies AB, Lund, Sweden). It was recommended that patients switch to agalsidase alfa due to a manufacturing shortage of agalsidase beta beginning in June 2009. This study assessed the effect of switching to agalsidase alfa on clinical outcomes in patients with AFD previously treated with agalsidase beta. Ten patients (seven male, three female) with genetically confirmed AFD and at least 48 months’ continuous data collected during treatment with agalsidase beta 1 mg/kg every other week were switched to agalsidase alfa 0.2 mg/kg every other week for at least 20 months, with prospective clinical evaluations every 6 months. Pre-switch data was collected retrospectively from patient charts. Cardiac functional parameters were assessed using magnetic resonance imaging. Results showed that renal function was normal (estimated glomerular filtration rate ≥90 mL/min/1.73 m2) in 8 of 10 patients prior to agalsidase alfa and generally remained stable after the switch. Cardiac mass decreased significantly (p < 0.05 vs pre-ERT) after agalsidase beta and remained unchanged after switching to agalsidase alfa. Symptoms of pain and health status scores did not deteriorate during agalsidase alfa therapy. Adverse events were mostly mild and infusion related. In conclusion, switching to agalsidase alfa was relatively well tolerated and associated with stable clinical status and preserved renal and cardiac function.Keywords
This publication has 35 references indexed in Scilit:
- The Effectiveness of Long-Term Agalsidase Alfa Therapy in the Treatment of Fabry NephropathyClinical Journal of the American Society of Nephrology, 2012
- Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patientsOrphanet Journal of Rare Diseases, 2011
- Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy2011
- Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT)Molecular Genetics and Metabolism, 2011
- Effects of enzyme replacement therapy in Fabry disease—A comprehensive review of the medical literatureGenetics in Medicine, 2010
- Therapeutic goals in the treatment of Fabry diseaseGenetics in Medicine, 2010
- Enzyme Replacement Therapy and Fabry NephropathyClinical Journal of the American Society of Nephrology, 2010
- Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry dataThe Lancet, 2009
- Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populationsNephrology Dialysis Transplantation, 2009
- Onset and progression of the Anderson–Fabry disease related cardiomyopathyInternational Journal of Cardiology, 2008